Distribution of brain metastases: low-risk metastasis areas may be avoided when treating with whole-brain radiotherapy.
Brain metastasis
Distribution
Whole-brain radiotherapy
Journal
Cancer imaging : the official publication of the International Cancer Imaging Society
ISSN: 1470-7330
Titre abrégé: Cancer Imaging
Pays: England
ID NLM: 101172931
Informations de publication
Date de publication:
22 Apr 2020
22 Apr 2020
Historique:
received:
04
02
2020
accepted:
15
04
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Previous work has demonstrated that metastases are not uniformly distributed across the brain. This study aims to determine there are low-risk brain metastasis (BM) areas that may be avoided during whole-brain radiotherapy (WBRT) to reduce neurocognitive toxicity. Clinical and magnetic resonance imaging (MRI) data of 991 metastases in 192 patients with advanced cancer were analyzed retrospectively. Eleven anatomically defined regions of interest (ROIs) were contoured, and the locations of the BMs were recorded. Using the same definition, ROIs were contoured in 20 healthy volunteers.The proportions of patients with BMs in different ROIs, proportion of BMs, and proportion of different ROI volumes relative to the total volume were calculated. The proportion of observed BMs was lower than expected in the brainstem, insula, diencephalon and internal structures, corpus callosum, and pituitary gland. The proportion of BMs was significantly higher than expected in the parietal lobe, occipital lobe, and cerebellum. For those patients with single BM, there was very low rate of low-risk ROIs involvement (0%), with 2-4 BMs, 6-13% of the patients had low-risk ROIs involvement, with ≥5 BMs, significant (> 30%) of the patients had low-risk ROIs involvement. The brainstem, insula, diencephalon and internal structures, corpus callosum, and pituitary gland demonstrate low risk for metastatic involvement. Involvement of low risk areas occurs in patients with more than 1 BM.
Identifiants
pubmed: 32321584
doi: 10.1186/s40644-020-00309-y
pii: 10.1186/s40644-020-00309-y
pmc: PMC7178626
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Subventions
Organisme : Mianyang Science and Technology Bureau
ID : 15-S01-3
Références
Tomography. 2017 Mar;3(1):16-22
pubmed: 28649664
J Radiat Res. 2013 Mar 1;54(2):285-91
pubmed: 23022606
JAMA. 2006 Jun 7;295(21):2483-91
pubmed: 16757720
Lancet. 2004 May 22;363(9422):1665-72
pubmed: 15158627
Oncotarget. 2015 Dec 22;6(41):44030-6
pubmed: 26536661
Minn Med. 2003 Dec;86(12):32-7
pubmed: 14719614
J Clin Oncol. 1988 Mar;6(3):543-51
pubmed: 3280744
Cancer Treat Rev. 2003 Dec;29(6):533-40
pubmed: 14585263
Cancer. 1983 Dec 15;52(12):2349-54
pubmed: 6640506
Br J Radiol. 2011 Jul;84(1003):649-58
pubmed: 21697413
Neuro Oncol. 2019 May 6;21(5):640-647
pubmed: 30715520
J Neurooncol. 2014 Nov;120(2):321-30
pubmed: 25048530
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):878-86
pubmed: 22172903
Radiother Oncol. 2010 Jun;95(3):327-31
pubmed: 20392503
J Neurooncol. 2010 Jan;96(1):45-68
pubmed: 19960227
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):669-73
pubmed: 2646260
J Clin Oncol. 2020 Apr 1;38(10):1019-1029
pubmed: 32058845
Arch Neurol. 1988 Jul;45(7):741-4
pubmed: 3390029
Magn Reson Imaging Clin N Am. 2011 Aug;19(3):429-37, vii
pubmed: 21816323
J Neurol. 2002 Oct;249(10):1357-69
pubmed: 12382150
Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):971-7
pubmed: 17446005
Klin Onkol. 2015;28(3):191-9
pubmed: 26062621